In Other News

• Study Reveals Immune Mechanism Driving Severe COVID-19 Progression

• PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers

• Cepheid Presents Third-Generation GeneXpert System at ADLM 2026

• Blood Protein Panel Predicts Timing of ALS Symptom Onset

• Collaboration Advances Sputum-Based Diagnostics for Asthma and COPD

• Study Reveals Immune Mechanism Driving Severe COVID-19 Progression

• Blood Gene Expression Fluctuates More Than Expected Over Time

• Siemens Adds CE-Marked Capillary Claims for 24 Assays on Atellica Analyzers

• Siemens Adds CE-Marked Capillary Claims for 24 Assays on Atellica Analyzers

• ADLM 2026 Explores Diabetes Milestones, Space Diagnostics, Alzheimer’s–Down Syndrome Links, and Cancer Advances

• Expanded Diagnostics and Therapies Target Rising Gonorrhea Resistance

• Genomic Test Helps Early Breast Cancer Patients Avoid Chemotherapy

• AI Digital Pathology Platform Standardizes IHC Scoring in Breast Cancer

• AI-Powered Genome Mapping Reveals New Layer of Alzheimer’s Disease Biology

• Residual Disease Test Predicts Merkel Cell Carcinoma Recurrence Earlier Than Antibody Assay

• Portable Rapid Test Aims to Detect Ebola at Point of Care

• AI-Powered Genome Mapping Reveals New Layer of Alzheimer’s Disease Biology

• Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis

• Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma

• Collaboration Advances Extracellular Vesicle-Based Tests for Neurodegenerative Diseases

• New Rapid Ebola Antigen Test Detects Infection at Point of Care

• Point-of-Care Molecular Technology Promises Transformative Shift in Oncology

• Preoperative Blood Test Predicts Colorectal Cancer Recurrence and Metastasis